Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Preferred Stock Liabilities (2021 - 2025)

Ani Pharmaceuticals' Preferred Stock Liabilities history spans 6 years, with the latest figure at $24.8 million for Q2 2025.

  • For Q2 2025, Preferred Stock Liabilities changed 0.0% year-over-year to $24.8 million; the TTM value through Jun 2025 reached $24.8 million, changed 0.0%, while the annual FY2024 figure was $24.8 million, 0.0% changed from the prior year.
  • Preferred Stock Liabilities for Q2 2025 was $24.8 million at Ani Pharmaceuticals, roughly flat from $24.8 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $24.8 million in Q4 2021 and bottomed at $24.8 million in Q4 2021.
  • The 5-year median for Preferred Stock Liabilities is $24.8 million (2021), against an average of $24.8 million.
  • The largest YoY upside for Preferred Stock Liabilities was 0.0% in 2022 against a maximum downside of 0.0% in 2022.
  • A 5-year view of Preferred Stock Liabilities shows it stood at $24.8 million in 2021, then changed by 0.0% to $24.8 million in 2022, then changed by 0.0% to $24.8 million in 2023, then changed by 0.0% to $24.8 million in 2024, then changed by 0.0% to $24.8 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Preferred Stock Liabilities are $24.8 million (Q2 2025), $24.8 million (Q1 2025), and $24.8 million (Q4 2024).